Healthcare / BiotechnologyHKSE
$1.28
+0.02 (+1.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $182.3M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
18.3x
↓EV/EBITDA
7.1x
↓ROE
4.4%
↑Gross Margin
34.6%
↓Debt/Equity
0.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-1.9%
FCF CAGR
—
FCF margin
9.2%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.99B · net income $167.3M · FCF $182.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.99B | $1.99B | $2.16B | $2.38B | $2.10B |
| Net Income | $167.3M | $167.3M | $-116.1M | $-528.5M | $287.5M |
| EBITDA | $563.5M | $563.5M | $331.8M | $-89.0M | $684.0M |
| EPS | 0.06 | 0.06 | -0.14 | -0.28 | 0.08 |
| Gross Margin | 34.6% | 34.6% | 34.3% | 34.3% | 30.9% |
| Operating Margin | 13.6% | 13.6% | 11.9% | 13.1% | 12.8% |
| Net Margin | 8.4% | 8.4% | -5.4% | -22.2% | 13.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.34 | 0.34 | 0.52 | 0.78 | 0.68 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $182.3M | $182.3M | $195.6M | $136.5M | $-488.5M |
| Returns | |||||
| ROE | 4.4% | 4.4% | -3.1% | -14.7% | 7.3% |
| Valuation | |||||
| P/E | 18.29 | 18.29 | — | — | 54.00 |
| EV/EBITDA | 7.12 | 7.12 | 8.49 | — | 15.16 |
| P/B | 0.97 | 0.97 | 0.53 | 0.99 | 2.18 |
| Growth & Yield | |||||
| Revenue Growth | -7.8% | -7.8% | -9.4% | 13.1% | — |
| EPS Growth | 142.9% | 142.9% | 50.0% | -450.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
23.7%
EPS terminal req.
$0.11
Spread vs growth
119.2%
5Y implied EPS CAGR
18.0%
EPS terminal req.
$0.14
Spread vs growth
124.8%
10Y implied EPS CAGR
13.9%
EPS terminal req.
$0.22
Spread vs growth
128.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → 0.06
Residual
-25.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.